Levodopa was shown to inhibit the proliferation of esophageal squamous cell carcinoma (ESCC) via down-regulating the levels of oxidative phosphorylation proteins which includes MT-CO3, SDHD and NDUFS4 (Li et al., 2020). This evidence concerns the gene NDUFS4 and esophageal squamous cell carcinoma.